510(k) K190968
K190968 is an FDA 510(k) premarket notification submitted by Microgenics Corporation for the device "CEDIA Benzodiazepine Assay". The FDA issued a decision of Substantially Equivalent on Dec 9, 2019. The device falls under product code JXM (Enzyme Immunoassay, Benzodiazepine), a Class II device regulated under 21 CFR 862.3170. Microgenics Corporation has 20 other 510(k) clearances on record.
Clearance details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- Dec 9, 2019
- Date Received
- Apr 12, 2019
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device classification
- Device Name
- Enzyme Immunoassay, Benzodiazepine
- Device Class
- Class II
- Regulation Number
- 862.3170
- Review Panel
- TX
- Submission Type
- 510(k)
Need the full FDA record for Microgenics Corporation? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.